ATC Index
Explore Pembrolizumab (Keytruda), a powerful immune checkpoint inhibitor for various cancers. Learn about its benefits, accurate dosage, and potential side effects.
Browse our catalog for available pharmaceutical products and competitive pricing.
Pembrolizumab is a highly effective humanized monoclonal antibody that functions as an immune checkpoint inhibitor. Marketed primarily under the brand name Keytruda, it has revolutionized the treatment landscape for numerous types of cancer by harnessing the body's own immune system to fight malignant cells. Developed through extensive research into cancer immunology, Pembrolizumab specifically targets the Programmed Death-1 (PD-1) receptor, a protein found on immune cells. By blocking this receptor, Pembrolizumab prevents cancer cells from evading detection and destruction by the immune system, thereby restoring and enhancing the anti-tumor immune response.
The journey of Pembrolizumab from laboratory to patient began with its initial accelerated approval by the U.S. Food and Drug Administration (FDA) in September 2014 for advanced melanoma that was unresectable or metastatic, following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This marked a significant milestone, as it was one of the first PD-1 inhibitors to receive such approval, paving the way for a new era of immunotherapy. Since its initial approval, the indications for Pembrolizumab have expanded dramatically, encompassing a wide array of solid tumors and hematologic malignancies, making it a cornerstone in modern oncology practices worldwide.
As a therapeutic agent, Pembrolizumab belongs to the drug class of immune checkpoint inhibitors, specifically a PD-1 blocking antibody. Its specific Anatomical Therapeutic Chemical (ATC) code is L01XC18, classifying it as an antineoplastic agent within the broader category of selective immunosuppressants. For the purpose of this article, and as specified, it is also associated with the ATC code I04. This classification underscores its role in modulating the immune system to exert its anti-cancer effects, distinguishing it from traditional chemotherapy agents or targeted therapies that directly attack cancer cells or specific pathways within them. The advent of drugs like Pembrolizumab represents a paradigm shift towards personalized and immune-mediated cancer treatments.
The therapeutic efficacy of Pembrolizumab stems from its precise mechanism of action involving the PD-1/PD-L1 pathway, a critical immune checkpoint that regulates T-cell activity. Under normal physiological conditions, the interaction between PD-1 (expressed on T-cells) and its ligands, PD-L1 and PD-L2 (expressed on various cells, including cancer cells), serves to dampen immune responses and prevent autoimmunity. However, many cancer cells exploit this pathway by overexpressing PD-L1, effectively creating an 'immune-privileged' environment that allows them to escape destruction by activated T-cells.
Pembrolizumab acts as a high-affinity humanized monoclonal antibody that selectively binds to the PD-1 receptor on T-cells. By blocking the binding of PD-L1 and PD-L2 to PD-1, Pembrolizumab disarms this immune evasion mechanism. This blockade effectively 'releases the brakes' on T-cells, allowing them to become reactivated, proliferate, and recognize and kill cancer cells more effectively. The restored T-cell activity leads to a robust anti-tumor immune response, resulting in tumor regression and improved patient outcomes across various cancer types.
Pembrolizumab has emerged as a versatile and highly effective immunotherapy, approved for the treatment of a broad spectrum of cancers. Its ability to activate the immune system against malignant cells has led to its adoption as a first-line or subsequent-line therapy, either as a monotherapy or in combination with other anti-cancer agents, significantly improving survival rates and quality of life for many patients.
The dosage and administration of Pembrolizumab are highly individualized, depending on the specific cancer type, patient's body weight, overall health, and response to treatment. It is administered intravenously (IV) by a healthcare professional in a clinical setting. Treatment cycles typically involve infusions over approximately 30 minutes, followed by a period of observation for potential infusion-related reactions. The duration of therapy can vary, often continuing until disease progression, unacceptable toxicity, or for a maximum of two years in some adjuvant settings.
| Indication | Typical Dose | Frequency | Route |
|---|---|---|---|
| Most Solid Tumors (e.g., Melanoma, NSCLC) | 200 mg | Every 3 weeks | Intravenous (IV) |
| Most Solid Tumors (Alternative Dosing) | 400 mg | Every 6 weeks | Intravenous (IV) |
| Adjuvant Melanoma | 200 mg | Every 3 weeks for up to 1 year | Intravenous (IV) |
| Classical Hodgkin Lymphoma | 200 mg (adults), 2 mg/kg (pediatric) | Every 3 weeks | Intravenous (IV) |
Important: Always follow your prescriber instructions. Dosages vary by weight, age, and condition.
While Pembrolizumab offers significant therapeutic benefits, like all potent medications, it can cause side effects. These are often immune-related adverse events (irAEs) due to its mechanism of action, which involves stimulating the immune system. Patients should be closely monitored for these effects, and early intervention is crucial for management.
Drug interactions with Pembrolizumab are primarily related to its immune-modulating effects. Concurrent use of certain medications can either diminish the efficacy of Pembrolizumab or increase the risk of immune-related adverse events. It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking.
Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
The safety of long-term use of Pembrolizumab has been evaluated in various clinical trials, with some patients receiving treatment for several years. While many patients tolerate it well, the risk of immune-related adverse events persists throughout the treatment duration and even after discontinuation. Regular monitoring by a healthcare professional is crucial to manage any potential side effects effectively. In some cases, treatment may be continued until disease progression or unacceptable toxicity, or for a fixed duration, such as two years in the adjuvant setting for melanoma.
Pembrolizumab is administered intravenously (IV) and is not affected by food intake. Patients can eat and drink normally before, during, and after their infusion, unless otherwise advised by their healthcare provider for specific medical reasons unrelated to the medication itself. There are no dietary restrictions directly associated with the administration of Pembrolizumab.
If you miss a scheduled dose of Pembrolizumab, it is crucial to contact your healthcare team immediately. They will advise you on the next steps, which may include administering the missed dose as soon as possible and adjusting the subsequent dosing schedule. It is important not to double your dose or attempt to self-adjust your treatment schedule, as this could lead to adverse effects or reduced efficacy.
Pembrolizumab is a prescription-only medication and is not available for direct purchase by individuals. It must be prescribed by a qualified physician, typically an oncologist, and administered in a clinical setting such as a hospital or an infusion center. Obtaining Pembrolizumab for sale requires a valid prescription and is typically handled through specialized pharmacy channels that work directly with healthcare providers and institutions. Patients should always obtain their medication through licensed medical channels to ensure authenticity, proper storage, and safe administration.
Chat on WhatsApp